Synthetic Biology continues to fight the battle against COVID-19

Pharma Tech Outlook: Pharma Tech Magazine

Synthetic Biology continues to fight the battle against COVID-19

Pharma Tech Outlook | Friday, December 11, 2020

The incredible, exhausting year of 2020 will soon be over, as we have been living with COVID-19 for almost one year. The emergence of COVID-19 has put a considerable amount of pressure and attention on global biotech’s ability to respond to deadly new diseases. However, the synthetic biology field responded very quickly and efficiently to the pandemic. Synthetic biology companies aim to provide the most advanced and cost-effective DNA technology platform to facilitate COVID-19 research for its diagnostics, therapeutics, and prevention.

As a professional and passionate synthetic biology company, Synbio Technologies has developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities and delivers satisfactory solutions to global researchers for various applications. Its small nucleic acid synthesis platform provides a wide range of large-scale DNA oligo/probe synthesis options, including COVID-19 related primers & probes, diagnostic oligos & probes, aptamers, antisense oligos, and standard or modified oligos. Synbio Technologies’s products, certified with ISO 9001 & ISO 13485 quality certifications, are widely used in precision medicine, genetic disease detection, infectious disease detection, food & agriculture industries, etc.

Since the outbreak of COVID-19, Synbio Technologies has set up an emergency coronavirus project team, working against time to produce virus-related probes, genes, and protein products. To support the global fight against COVID-19, the company will always expedite the synthesis and delivery processes of all COVID-19 related primers and probes, as well as any other novel coronavirus related products. Not to mention, this all includes24/7 professional online support. Synbio Technologies has manufactured a detection assay kit based on the CDC’s Real-Time RT-PCR protocol for COVID-19 detection. This assay has successfully detected SARS-CoV-2 in positive control samples such as N genes and human RNase P (RNP). Synbio Technologies has also provided a series of primers and probes for COVID-19 detection in batches according to the latest official WHO and CDC documents. This guarantees the daily production capacity of roughly one million nucleic acid diagnostic probe kits in order to accelerate disease detection and research.

Synbio Technologies was listed as one of the top Drug Discovery and Development Consulting/Service Companies in2020 by Pharma Tech Outlook magazine. The company will consistently offer tailor-made approaches to accomplish every oligo & probe synthesis request.


Weekly Brief

Read Also